Literature DB >> 26816105

Prognostic factors and long-term survival in surgically treated brain metastases from non-small cell lung cancer.

Frederik Enders1, Christoph Geisenberger2, Christine Jungk2, Justo Lorenzo Bermejo3, Rolf Warta2, Andreas von Deimling4, Christel Herold-Mende2, Andreas Unterberg2.   

Abstract

OBJECTIVE: Brain metastases (BMs) are the most common malignant brain tumors in adults. Despite multimodal treatment options such as microsurgery, radiotherapy and chemotherapy, prognosis still remains very poor. Non-small cell lung cancer (NSCLC) constitutes the most common source of brain metastases. In this study, prognostic factors in this patient population were identified through an in-depth analysis of clinical parameters of patients with BMs from NSCLC. PATIENTS AND METHODS: Clinical data of 114 NSCLC cancer patients who underwent surgery for BMs at the University Hospital Heidelberg were retrospectively reviewed for age, gender, type of treatment, time course of the disease, presence of neurologic symptoms, Karnofsky Performance Status (KPS), smoking history, presence of extracranial metastases at initial diagnosis of NSCLC, number, location and size of brain metastases. Univariate and multivariate survival analyses were performed using the Log-rank test and Cox' proportional hazard model, respectively.
RESULTS: Median survival time from surgery for BMs was 11.2 months. 18.4% (21 of 114) patients were long-term survivors (>24 months; range 26.3-75.1 months). Age, gender, size and number of intracranial metastases were not significantly associated with patient survival. Univariate analysis identified complete resection, postoperative whole brain radiotherapy (WBRT) and a preoperative KPS of >80% as positive prognostic factors. Infratentorial location and presence of extracranial metastases were shown to be negative prognostic factors. Surgery for the primary tumor was associated with a superior patient outcome both in univariate and multivariate analyses.
CONCLUSION: Our data strongly suggest that surgical treatment of the primary tumor and complete resection of brain metastases in NSCLC patients followed by WBRT improve survival. Moreover, long-term survivors (>2 years) were more frequent than previously reported.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain metastases; Long-term survivors; NSCLC; Prognostic factors; Treatment

Mesh:

Year:  2016        PMID: 26816105     DOI: 10.1016/j.clineuro.2016.01.011

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  16 in total

1.  Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literature.

Authors:  Concetta Elisa Onesti; Daniela Iacono; Silvia Angelini; Salvatore Lauro; Marco Mazzotta; Mario Alberto Occhipinti; Raffaele Giusti; Paolo Marchetti
Journal:  Transl Lung Cancer Res       Date:  2016-12

2.  Can anticancer chemotherapy promote the progression of brain metastases?

Authors:  Aymeric Amelot; Louis-Marie Terrier; Bertrand Mathon; Ann-Rose Cook; Jean-Jacques Mazeron; Charles-Ambroise Valery; Philippe Cornu; Marc Leveque; Alexandre Carpentier
Journal:  Med Oncol       Date:  2018-02-09       Impact factor: 3.064

3.  The TNM 8 M1b and M1c classification for non-small cell lung cancer in a cohort of patients with brain metastases.

Authors:  C Nieder; M Hintz; O Oehlke; A Bilger; A L Grosu
Journal:  Clin Transl Oncol       Date:  2017-03-29       Impact factor: 3.405

4.  Surgical resection of brain metastases prolongs overall survival in non-small-cell lung cancer.

Authors:  Chia-Te Yen; Wen-Jui Wu; Yen-Ting Chen; Wei-Chin Chang; Sheng-Hsiung Yang; Sheng-Yeh Shen; Jian Su; Hsuan-Yu Chen
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

5.  Risk factor of brain metastases and its influence on patient prognosis after complete resection of non-small cell lung cancer.

Authors:  Jinlei Li
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

6.  Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA).

Authors:  Carsten Nieder; Mandy Hintz; Oliver Oehlke; Angelika Bilger; Anca L Grosu
Journal:  Radiat Oncol       Date:  2017-06-26       Impact factor: 3.481

7.  Brain imaging before primary lung cancer resection: a controversial topic.

Authors:  Zoe Hudson; Eveline Internullo; Anthony Edey; Isabel Laurence; Davide Bianchi; Alfredo Addeo
Journal:  Ecancermedicalscience       Date:  2017-06-20

Review 8.  Brain metastases from hepatocellular carcinoma: recent advances and future avenues.

Authors:  Shanshan Wang; Anqiang Wang; Jianzhen Lin; Yuan Xie; Liangcai Wu; Hanchun Huang; Jin Bian; Xiaobo Yang; Xueshuai Wan; Haitao Zhao; Jiefu Huang
Journal:  Oncotarget       Date:  2017-04-11

9.  A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases.

Authors:  Thiago Pimentel Muniz; Victor Hugo Fonseca de Jesus; Victor Aurélio Ramos Sousa; Malu Viter da Rosa Barbosa; Vladmir Cláudio Cordeiro de Lima
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

Review 10.  Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion.

Authors:  Matthias Preusser; Frank Winkler; Manuel Valiente; Christian Manegold; Elizabeth Moyal; Georg Widhalm; Jörg-Christian Tonn; Christoph Zielinski
Journal:  ESMO Open       Date:  2018-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.